• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ESTRONE SODIUM SULFATE Drug Record

  • Summary
  • Interactions
  • Claims
  • ESTRONE SODIUM SULFATE chembl:CHEMBL2106240

    Alternate Names:

    ESTRONE SODIUM SULFATE
    MORESTIN
    ENJUVIA
    EVEX
    CONESTORAL
    17-OXOESTRA-1,3,5(10)-TRIEN-3-YL SODIUM SULFATE
    CONJUGATED ESTROGEN
    ESTROGENIC SUBSTANCES (CONJUGATED)
    OESTRONE-3-SULPHATE SODIUM SALT
    SODIUM ESTRONE 3-SULFATE
    PREMARIN
    ESTRONE-3-SULFATE SODIUM SALT
    HYHORIN
    ESTRONE SULFATE SODIUM
    ESTROGENS
    ESTROGENS, CONJUGATED
    CENESTIN
    CONJUGATED ESTROGENS
    chembl:CHEMBL2106240
    chemidplus:438-67-5
    pubchem.compound:23667301
    drugbank:00286

    Drug Info:

    (0 More Sources)

    Publications:

    Santamaría A et al., 2001, Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene., Haematologica
    Wu O et al., 2005, Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study., Thromb Haemost
    Herrington DM et al., 2002, Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease., Arterioscler Thromb Vasc Biol
    Oger E et al., 2003, Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial., Arterioscler Thromb Vasc Biol
    Straczek C et al., 2005, Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration., Circulation
    Andersen BS et al., 1998, Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism., Thromb Haemost
    Martinelli I et al., 1999, Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis., Arterioscler Thromb Vasc Biol
    Cushman M et al., 2004, Estrogen plus progestin and risk of venous thrombosis., JAMA
    Kemmeren JM et al., 2002, Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation., Thromb Haemost
    Spannagl M et al., 2000, Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?, Eur J Contracept Reprod Health Care
    Legnani C et al., 2002, Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use., Eur Heart J
    Kemmeren JM et al., 2002, Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation., Blood Coagul Fibrinolysis
    Kemmeren JM et al., 2004, Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial., Blood
    Vandenbroucke JP et al., 1994, Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation., Lancet
    Høibraaten E et al., 2001, Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial., Br J Haematol
    Spink BC et al., 2000, SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells., Carcinogenesis
    Adjei AA et al., 2002, Catecholestrogen sulfation: possible role in carcinogenesis., Biochem Biophys Res Commun
    Nishiyama T et al., 2002, Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases., Biochem Pharmacol
    Falany CN, 1997, Enzymology of human cytosolic sulfotransferases., FASEB J
  • ESTRONE SODIUM SULFATE   F5

    Interaction Score: 41.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11532625 16113779 12067913 12869355 16301339 9459317 10073976 15467059 11859850 10943572 12069454 12138364 14551147 7968118 11703344


    Sources:
    PharmGKB

  • ESTRONE SODIUM SULFATE   SULT1A1

    Interaction Score: 23.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11062153 11906176 12034366 9068609


    Sources:
    PharmGKB

  • PharmGKB: estrogens

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Santamaría A et al., 2001, Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene., Haematologica
    Wu O et al., 2005, Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study., Thromb Haemost
    Herrington DM et al., 2002, Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease., Arterioscler Thromb Vasc Biol

  • ChemblDrugs: chembl:CHEMBL2106240

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21